JP2000503003A - 多段階カスケード増強ワクチンの効果を高めるための免疫接合体の使用 - Google Patents
多段階カスケード増強ワクチンの効果を高めるための免疫接合体の使用Info
- Publication number
- JP2000503003A JP2000503003A JP09523703A JP52370397A JP2000503003A JP 2000503003 A JP2000503003 A JP 2000503003A JP 09523703 A JP09523703 A JP 09523703A JP 52370397 A JP52370397 A JP 52370397A JP 2000503003 A JP2000503003 A JP 2000503003A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- vaccine
- cea
- inter
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 111
- 229940127121 immunoconjugate Drugs 0.000 title claims abstract description 45
- 230000002708 enhancing effect Effects 0.000 title description 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 80
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 74
- 239000000427 antigen Substances 0.000 claims abstract description 61
- 108091007433 antigens Proteins 0.000 claims abstract description 61
- 102000036639 antigens Human genes 0.000 claims abstract description 61
- 102000004127 Cytokines Human genes 0.000 claims abstract description 26
- 108090000695 Cytokines Proteins 0.000 claims abstract description 26
- 230000028993 immune response Effects 0.000 claims abstract description 26
- 239000012678 infectious agent Substances 0.000 claims abstract description 22
- 230000003302 anti-idiotype Effects 0.000 claims abstract description 18
- 230000024932 T cell mediated immunity Effects 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims description 106
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 61
- 230000002494 anti-cea effect Effects 0.000 claims description 41
- 230000000890 antigenic effect Effects 0.000 claims description 38
- 241000124008 Mammalia Species 0.000 claims description 34
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 32
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 32
- 241001529936 Murinae Species 0.000 claims description 25
- 108010002350 Interleukin-2 Proteins 0.000 claims description 20
- 102000000588 Interleukin-2 Human genes 0.000 claims description 20
- 238000001990 intravenous administration Methods 0.000 claims description 20
- 108010065805 Interleukin-12 Proteins 0.000 claims description 16
- 102000013462 Interleukin-12 Human genes 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 15
- 230000001939 inductive effect Effects 0.000 claims description 14
- 230000027455 binding Effects 0.000 claims description 12
- 102000014914 Carrier Proteins Human genes 0.000 claims description 11
- 108010078791 Carrier Proteins Proteins 0.000 claims description 11
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 11
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 11
- 230000028996 humoral immune response Effects 0.000 claims description 10
- 102000008070 Interferon-gamma Human genes 0.000 claims description 9
- 108010074328 Interferon-gamma Proteins 0.000 claims description 9
- 230000002163 immunogen Effects 0.000 claims description 9
- 229960003130 interferon gamma Drugs 0.000 claims description 9
- 229940117681 interleukin-12 Drugs 0.000 claims description 9
- 108010068647 P2 peptide Proteins 0.000 claims description 8
- 108010055044 Tetanus Toxin Proteins 0.000 claims description 6
- 229940118376 tetanus toxin Drugs 0.000 claims description 6
- 238000007920 subcutaneous administration Methods 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 230000036039 immunity Effects 0.000 claims description 3
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 29
- 210000004881 tumor cell Anatomy 0.000 abstract description 18
- 241001465754 Metazoa Species 0.000 abstract description 7
- 230000008348 humoral response Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 description 53
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 47
- 210000004027 cell Anatomy 0.000 description 36
- 201000011510 cancer Diseases 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 24
- 238000004519 manufacturing process Methods 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 15
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000004408 hybridoma Anatomy 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 238000007429 general method Methods 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 230000002458 infectious effect Effects 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 238000010353 genetic engineering Methods 0.000 description 6
- 125000005647 linker group Chemical group 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 229940027941 immunoglobulin g Drugs 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 125000003396 thiol group Chemical class [H]S* 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 244000045947 parasite Species 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 102100034256 Mucin-1 Human genes 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000013599 cloning vector Substances 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- -1 Enzymatic Substances 0.000 description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010011301 Interleukin-12 Subunit p35 Proteins 0.000 description 2
- 102000014154 Interleukin-12 Subunit p35 Human genes 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- 150000004753 Schiff bases Chemical class 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000007469 bone scintigraphy Methods 0.000 description 2
- 125000000837 carbohydrate group Chemical group 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 150000002466 imines Chemical group 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000001006 meconium Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000000581 natural killer T-cell Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- XQUPVDVFXZDTLT-UHFFFAOYSA-N 1-[4-[[4-(2,5-dioxopyrrol-1-yl)phenyl]methyl]phenyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1C(C=C1)=CC=C1CC1=CC=C(N2C(C=CC2=O)=O)C=C1 XQUPVDVFXZDTLT-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- DHGZZGFKARJISD-UHFFFAOYSA-N 2,4-diphenyl-1,3-thiazole-5-carbonyl chloride Chemical compound ClC(=O)C=1SC(C=2C=CC=CC=2)=NC=1C1=CC=CC=C1 DHGZZGFKARJISD-UHFFFAOYSA-N 0.000 description 1
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
- 229960005508 8-azaguanine Drugs 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 244000117499 Colubrina elliptica Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 101100075837 Drosophila melanogaster Mabi gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical group F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000228402 Histoplasma Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 101800004191 Peptide P2 Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920001054 Poly(ethylene‐co‐vinyl acetate) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000002848 Schistosomiasis mansoni Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010029157 Sialic Acid Binding Ig-like Lectin 2 Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 1
- 241000375392 Tana Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229940099550 actimmune Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011613 copenhagen rat Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000032832 immune response to tumor cell Effects 0.000 description 1
- 229940124452 immunizing agent Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 108010042414 interferon gamma-1b Proteins 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 108010091867 peptide P Proteins 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000006941 response to substance Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000036332 sexual response Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229950001699 teceleukin Drugs 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.(a)(i)HLD−DR−吹き剛体に結合する抗体成分と、 (ii)抗原性ペプチドであって、TAA又は抗原関連の該感染性 物質のエピト−プいずれか一種を含む該抗原性ペプチドと を含んでなる該第一ワクチンを哺乳動物に皮内投与することと、 (b)該哺乳動物に該ワクチンを静脈内投与することと を含んでなる、腫瘍関連抗原(TAA)を発現する、あるいは感染性物質に起因 する哺乳動物の腫瘍に対する体液性および細胞性の免疫応答を誘導する方法。 2.上記の抗体成分が (a)ネズミ・モノクロナ−ル抗体と、 (b)ネズミ・モノクロナ−ル抗体から誘導されるヒト化抗体と、 (c)ヒト・モノクロナ−ル抗体と、 (d)(a),(b)または(c)から誘導される抗体フラグメント と からなる群から選ばれる、請求項1に記載の方法。 3.上記抗体フラグメントが、F(ab`)2,F(ab)2,Fab’,Fab,Fv,sFvお よび最小認識単位(minimal recognition unit)からなる群から選ばれる、請求 項2に記載の方法。 4.上記方法がさらに、上記哺乳動物に対する上記ワクチンの静脈内投与前お よびその投与中にインタ−ロイキン2、インタ−フェロンγおよびインタ−ロイ キン12を投与することからなる、請求項1に記載の方法。 5.上記方法がさらに、上記第一ワクチンの皮内投与後、モノクロナール抗体 とサイトカインまたはリンホカインとの接合体を投与することからなる、請求項 1に記載の方法。 6.(a)第一ワクチンであって、 (i)HLD−DR−複合体に結合する抗体成分と、 (ii)主要組識適合性(MHC)制限免疫応答を誘導する抗原性ペ プチドと を含んでなる該第一ワクチンを哺乳動物に皮内投与することと、 (b)該哺乳動物に該ワクチンを静脈内投与することと を含んでなる、腫瘍関連抗原(TAA)を発現する哺乳動物の腫瘍に対する体液 性および細胞性免疫応答を誘導する方法。 7.上記抗体成分が (a)ネズミ・モノクロナ−ル抗体と、 (b)ネズミ・モノクロナ−ル抗体から誘導されるヒト化抗体と、 (c)ヒト・モノクロナ−ル抗体と、 (d)(a),(b)または(c)から誘導される抗体フラグメント と からなる群から選ばれる、請求項6に記載の方法。 8.上記抗体フラグメントが、F(ab`)2,F(ab)2,Fab',Fab,Fv,sFvおよ び最小認識単位からなる群から選ばれる、請求項6に記載の方法。 9.上記方法がさらに、上記哺乳動物に対する上記ワクチンの静脈内投与前お よびその投与中にインタ−ロイキン2、インタ−フェロンγおよびインタ−ロイ キン12からなる群から選ばれるサイトカイン少なくとも一種を投与することか らなる、請求項6に記載の方法。 10.上記抗原性ペプチドがテタナス毒素P2ペプチドである請求項6に記載 の方法。 11.上記方法がさらに、上記第一ワクチンの皮内投与後、モノクロナ−ル抗 体とサイトカインまたはリンホカインとの接合体を投与することからなる、請求 項6に記載の方法。 12.さらに、第二ワクチンを静脈内投与することからなり、該第二ワクチン が (i)TAAに結合する抗体成分と、 (ii)MHC制限免疫応答を誘導する抗原性ペプチドと を含んでなる免疫接合体を含有している、請求項6に記載の方法。 13.上記第二ワクチンの上記抗原性ペプチドがテタナス毒素P2ペプチドで ある請求項12に記載の方法。 14.上記方法がさらに、上記哺乳動物に対する上記第二ワクチンの静脈内投 与前およびその投与中にインタ−ロイキン2、インタ−ロイキン12およびイン ターフェロンγからなる群から選ばれるサイトカイン少なくとも一種をを投与す ることからなる、請求項6に記載の方法。 15.(a)第一ワクチンがCEAに結合する抗体成分からなり、該抗体成分 が可溶の免疫原性担体タンパクと接合している該第一ワクチンを哺乳動物に皮内 投与することと、 (b)第二ワクチンが該CEAのエピト−プを擬態する抗イデイオタイプ抗体 フラグメントからなり、該イディオタイプ抗体フラグメントが可溶の免疫原性担 体タンパクと接合している該第二ワクチンを哺乳動物に皮内投与することと、 (c)第三ワクチンがCEAのエピト−プからなる抗原性ペプチドとHLA− DR複合体に結合する抗体成分とを含む免疫接合体からなり、該第三ワクチンを 該哺乳動物に投与することと からなるがん胎児性抗原(CEA)を発現する哺乳動物の腫瘍に対する体液性お よび細胞性免疫応答を誘導する方法。 16.上記第三ワクチンの上記抗原性ペプチドがCEAのA3B3領域からな る、請求項15に記載の方法。 17.上記第三ワクチンの上記抗原性ペプチドが上記CEAのエピト−プを擬 態する抗イディオタイプ抗体の最小認識単位からなる、請求項14に記載の方法 。 18.上記第一ワクチンの上記抗体成分が (a)ネズミ・モノクロナ−ル第三種抗CEA抗体と、 (b)ネズミ・モノクロナ−ル第三種抗CEA抗体から誘導されるヒト化抗体 と、 (c)ヒト・モノクロナ−ル抗CEA抗体と、 (d)(a),(b)または(c)から誘導される抗体フラグメントとからな る群から選ばれる、請求項15に記載の方法。 19.上記抗体フラグメントが、F(ab`)2,F(ab)2,Fab',Fab,Fv,sFvお よび最小認識単位からなる群から選ばれる、請求項18に記載の方法。 20.上記抗イディオタイプ抗体フラグメントが (a)第三種抗CEA抗体の可変部に結合するポリクロナ−ル抗体と、 (b)第三種抗CEA抗体の可変部に結合するネズミ・ポリクロナ−ル抗体と 、 (c)(b)から誘導されるヒト化抗体と、 (d)第三種抗CEA抗体の可変部に結合するヒト・ポリクロナ−ル抗体と、 (e)第三種抗CEA抗体の可変部に結合する類人霊長類ポリクロナ−ル抗体 と、 (f)(a)、(b)、(c)、(d)または(e)から誘導される抗体フラ グメントと からなる群から選ばれる、請求項15に記載の方法。 21.上記抗体フラグメントが、F(ab`)2,F(ab)2,Fab',Fab,Fv,sFvお よび最小認識単位からなる群から選ばれる、請求項20に記載の方法。 22.上記方法がさらに、上記第二ワクチンの投与前およびその投与中にイン タ−ロイキン2、インタ−フェロンγおよびインタ−ロイキン12からなる群か ら選ばれるサイトカイン少なくとも一種をを投与することからなる、請求項15 に記載の方法。 23.上記方法がさらに、モノクロナ−ル抗体とサイトカインまたはリンホカ インとの接合体を投与することからなる、請求項15に記載の方法。 24.腫瘍関連抗原(TAA)を発現する腫瘍に対して、または感染性物質に 起因する疾患に対して、患者の体液性および細胞性免疫応答を誘導する改良方法 に使用するための医薬製剤中における、 (i)HLA−DR複合体に結合する抗体成分と、 (ii)抗原性ペプチドであって、TAAまたは上記感染性物質の関連抗原の エピト−プ少なくとも一種を含む該抗原性ペプチドと からなる免疫接合体を含むワクチンの使用であって、該患者に対して、 (a)該ワクチンの皮下投与と、 (b)該ワクチンの静脈内投与と を行う使用。 25.腫瘍関連抗原(TAA)を発現する腫瘍に対して、または感染性物質に 起因する疾患に対して、患者の体液性および細胞性免疫応答を誘導する改良方法 に使用するための医薬製剤中における、 (i)HLA−DR複合体に結合する抗体成分と、 (ii)主要組識適合性(MHC)制限免疫応答を誘導する該抗原性ペプチド と からなる免疫接合体を含むワクチンの使用であって、該患者に対して、 (a)該ワクチンの皮下投与と、 (b)該ワクチンの静脈内投与と を行う使用。 26.腫瘍関連抗原(TAA)を発現する腫瘍に対して、患者の体液性および 細胞性免疫応答を誘導する改良方法に使用するための医薬製剤中における、 (1)(i)HLA−DR−複合体に結合する抗体成分、および (ii)主要組識適合性(MHC)制限免疫応答を誘導する該抗原性ペ プチドと を含んでなる免疫接合体を含む第一ワクチンと、 (2)(i)TAAに結合する抗体成分と、 (ii)MHC制限免疫応答を誘導する該抗原性ペプチドと を含んでなる免疫接合体を含む第二ワクチン の使用であって、該患者に対して、 (a)該第一ワクチンの皮下投与と、 (b)該第一ワクチンの静脈内投与と、 (c)該第二ワクチンの静脈内投与と を行う使用。 27.がん胎児性抗原(CEA)を発現する腫瘍に対して、哺乳動物の体液性 および細胞性免疫応答を誘導する改良方法に使用するための医薬製剤中における 、 (1)CEAに結合し、且つ可溶の免疫原性担体タンパクと接合する抗体成分 からなる第一ワクチンと、 (2)該CEAのエピト−プを擬態する抗イディオタイプ抗体成分からなり、 該抗イディオタイプ抗体成分が可溶の免疫原性担体タンパクと接合する、第二ワ クチンと、 (3)CEAのエピト−プを含む抗原性ペプチドとHLA−DR複合体に結合 する抗体成分とからなる免疫接合体を含む第三ワクチンと の使用であって、該患者に対して (a)該第一ワクチンの投与と、 (b)該第二ワクチンの投与と、 (c)該第三ワクチンの投与 を行う使用。 28.上記抗体成分が (a)ネズミ・モノクロナ−ル抗体と (b)ネズミ・モノクロナ−ル抗体から誘導されるヒト化抗体と、 (c)ヒト・モノクロナ−ル抗体と、 (d)(a),(b)または(c)から誘導される抗体フラグメントと からなる群から選ばれる、請求項24ないし27のいずれかに記載の使用。 29.上記抗体フラグメントが、F(ab‘)2,F(ab)2,Fab’, Fab,Fv,sFvおよび最小認識単位からなる群から選ばれる、請求項24ない し27のいずれかに記載の使用。 30.上記医薬製剤ががさらに、インタ−ロイキン2、インタ−ロイキン12 およびインタ−フェロンγからなる群から選ばれるサイトカイン少なくとも一種 を含み、且つ、上記ワクチンの静脈内投与前およびその投与中に上記患者にサイ トカイン少なくとも一種を投与する、請求項24または25のいずれかに記載の 使用。 31.上記医薬製剤ががさらに、インタ−ロイキン2、インタ−ロイキン12 およびインタ−フェロンγからなる群から選ばれるサイトカイン少なくとも一種 を含んでなり、且つ、上記ワクチンの静脈内投与前およびその投与中に上記患者 にサイトカイン少なくとも一種を投与する、請求項26または27のいずれかに 記載の使用。 32.上記抗原性ペプチドがテタナス毒素P2ペプチドである請求項24また は25のいずれかに記載の使用。 33.上記第三ワクチンの上記抗原性ペプチドがCEAのA3B3領域からな る、請求項27に記載の使用。 34.上記第三ワクチンの上記抗原性ペプチドが、上記CEAのエピト−プを 擬態する抗イディオタイプ抗体の最小認識単位からなる、請求項27に記載の使 用。 35.上記第三ワクチンの上記抗体成分が (i)ネズミ・モノクロナ−ル第三種抗CEA抗体と、 (ii)ネズミ・モノクロナ−ル第三種抗CEA抗体から誘導されるヒト化抗 体と、 (iii)ヒト・モノクロナール抗CEA抗体と、 (iv)(i),(ii)または(iii)から誘導される抗体フラグメント と、 からなる群から選ばれる、請求項27に記載の使用。 36.上記第二ワクチンの上記抗イディオタイプ抗体フラグメントが (i)第三種抗CEA抗体の可変部に結合するポリクロナール抗体と、 (ii)第三種抗CEA抗体の可変部に結合するネズミ・ポリクロナ−ル抗体 と、 (iii)(ii)から誘導されるヒト化抗体と、 (iv)第三種抗CEA抗体の可変部に結合するヒト・モノクロナ−ル抗体と (v)第三種抗CEA抗体の可変部に結合する類人霊長類ポリクロナ−ル抗体 と、 (vi)(i)、(ii)、(iii)、(iv)または(v)から誘導され る抗体フラグメントと からなる群から選ばれる、請求項27に記載の方法。 37.上記医療製剤ががさらに、上記哺乳動物に対する上記ワクチンの静脈内投 与前およびその投与中にインタ−ロイキン−2、インタ−ロイキン−12および インタ−フェロン−γからなる群から選ばれるサイトカイン少なくとも一種を投 与することからなる、請求項24または25のいずれかに記載の使用。 38.上記医薬製剤ががさらに、モノクロナ−ル抗体と、サイトカインまたは リンホカインとの接合体からなり、上記ワクチンの皮内投与後にこのMabとサ イトカインまたはリンホカインの接合体を上記患者に投与する、請求項24ない し26のいずれかに記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/577,106 | 1995-12-22 | ||
US08/577,106 US7354587B1 (en) | 1994-07-06 | 1995-12-22 | Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines |
PCT/US1996/019755 WO1997023237A1 (en) | 1995-12-22 | 1996-12-20 | Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008016220A Division JP2008115196A (ja) | 1995-12-22 | 2008-01-28 | 多段階カスケード増強ワクチンの効果を高めるための免疫接合体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000503003A true JP2000503003A (ja) | 2000-03-14 |
JP2000503003A5 JP2000503003A5 (ja) | 2004-11-04 |
Family
ID=24307306
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP09523703A Withdrawn JP2000503003A (ja) | 1995-12-22 | 1996-12-20 | 多段階カスケード増強ワクチンの効果を高めるための免疫接合体の使用 |
JP2008016220A Pending JP2008115196A (ja) | 1995-12-22 | 2008-01-28 | 多段階カスケード増強ワクチンの効果を高めるための免疫接合体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008016220A Pending JP2008115196A (ja) | 1995-12-22 | 2008-01-28 | 多段階カスケード増強ワクチンの効果を高めるための免疫接合体 |
Country Status (5)
Country | Link |
---|---|
EP (2) | EP2057999A3 (ja) |
JP (2) | JP2000503003A (ja) |
AU (1) | AU721927B2 (ja) |
CA (1) | CA2240834C (ja) |
WO (1) | WO1997023237A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014185179A (ja) * | 2007-05-31 | 2014-10-02 | Academisch Ziekenhuis Leiden Hodn Lumc | 皮内hpvペプチドワクチン接種 |
JP2015516376A (ja) * | 2012-03-19 | 2015-06-11 | ドイチェス クレブスフォルシュンクスツェントルム | T細胞エピトープを含む、b細胞受容体複合体結合タンパク質 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU737717B2 (en) * | 1997-08-13 | 2001-08-30 | Uab Research Foundation, The | Vaccination by topical application of genetic vectors |
AU2994599A (en) * | 1998-03-06 | 1999-09-20 | Imclone Systems Incorporated | Active immunization against angiogenesis-associated antigens |
JP2002515460A (ja) * | 1998-05-20 | 2002-05-28 | イムノメディクス, インコーポレイテッド | 二重特異性抗hlaクラスii不変鎖x抗病原体抗体を使用した治療 |
AU782160B2 (en) * | 1999-06-09 | 2005-07-07 | Immunomedics Inc. | Immunotherapy of autoimmune disorders using antibodies which target B-cells |
EP1221961A4 (en) * | 1999-10-13 | 2004-03-31 | Roswell Park Memorial Inst | INDUCTION OF A STRONG IMMUNE RESPONSE TO A TUMOR-RELATED SELF-ANTIGEN |
JP4212921B2 (ja) | 2002-03-29 | 2009-01-21 | 独立行政法人科学技術振興機構 | 抗体を提示するタンパク質中空ナノ粒子を用いる治療薬剤およびタンパク質中空ナノ粒子 |
TWI434855B (zh) * | 2006-11-21 | 2014-04-21 | Hoffmann La Roche | 結合物及其在免疫分析中作為參考標準之用途 |
TWI438675B (zh) | 2010-04-30 | 2014-05-21 | Ibm | 提供情境感知援助說明之方法、裝置及電腦程式產品 |
EP3138581B1 (en) * | 2011-03-17 | 2019-01-02 | The University of Birmingham | Re-directed immunotherapy |
GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
GB201216649D0 (en) * | 2012-09-18 | 2012-10-31 | Univ Birmingham | Agents and methods |
WO2016126611A1 (en) | 2015-02-02 | 2016-08-11 | The University Of Birmingham | Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes |
ES2873846T3 (es) | 2015-11-19 | 2021-11-04 | Revitope Ltd | Complementación de fragmento de anticuerpo funcional para un sistema de dos componentes para eliminación redirigida de células no deseadas |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
US4818709A (en) | 1983-01-21 | 1989-04-04 | Primus Frederick J | CEA-family antigens, Anti-CEA antibodies and CEA immunoassay |
US5851526A (en) * | 1985-04-19 | 1998-12-22 | Ludwig Institute For Cancer Research | Methods of treating colon cancer utilizing tumor-specific antibodies |
US5525338A (en) | 1992-08-21 | 1996-06-11 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin conjugates |
US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
US5194254A (en) * | 1986-05-06 | 1993-03-16 | Connaught Laboratories Limited | Enhancement of antigen immunogenicity |
GB8610983D0 (en) * | 1986-05-06 | 1986-06-11 | Connaught Lab | Enhancement of antigen immunogenicity |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DK8189A (da) * | 1988-01-12 | 1989-07-13 | Bunge Australia | Antigen-antistof-konjugater, deres fremstilling og anvendelse |
EP0438803B1 (en) | 1990-01-26 | 1997-03-12 | Immunomedics, Inc. | Vaccines against cancer and infectious diseases |
US5443953A (en) | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
AU701302B2 (en) * | 1994-05-13 | 1999-01-21 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Improvements in or relating to peptide delivery |
US5686578A (en) * | 1994-08-05 | 1997-11-11 | Immunomedics, Inc. | Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype |
US6328962B2 (en) * | 1995-06-07 | 2001-12-11 | Aventis Pasteur Limited | Method for delivery of antigens to selected cells of the immune system using chimeric antibodies |
-
1996
- 1996-12-20 EP EP09002533A patent/EP2057999A3/en not_active Ceased
- 1996-12-20 CA CA2240834A patent/CA2240834C/en not_active Expired - Fee Related
- 1996-12-20 JP JP09523703A patent/JP2000503003A/ja not_active Withdrawn
- 1996-12-20 AU AU12871/97A patent/AU721927B2/en not_active Ceased
- 1996-12-20 WO PCT/US1996/019755 patent/WO1997023237A1/en active Application Filing
- 1996-12-20 EP EP96943706A patent/EP0881910A4/en not_active Ceased
-
2008
- 2008-01-28 JP JP2008016220A patent/JP2008115196A/ja active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014185179A (ja) * | 2007-05-31 | 2014-10-02 | Academisch Ziekenhuis Leiden Hodn Lumc | 皮内hpvペプチドワクチン接種 |
JP2015516376A (ja) * | 2012-03-19 | 2015-06-11 | ドイチェス クレブスフォルシュンクスツェントルム | T細胞エピトープを含む、b細胞受容体複合体結合タンパク質 |
Also Published As
Publication number | Publication date |
---|---|
AU1287197A (en) | 1997-07-17 |
CA2240834A1 (en) | 1997-07-03 |
WO1997023237A1 (en) | 1997-07-03 |
EP0881910A4 (en) | 2006-05-03 |
CA2240834C (en) | 2013-12-03 |
EP2057999A2 (en) | 2009-05-13 |
AU721927B2 (en) | 2000-07-20 |
EP2057999A3 (en) | 2009-07-29 |
JP2008115196A (ja) | 2008-05-22 |
EP0881910A1 (en) | 1998-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3769014B2 (ja) | 多段カスケード型追加免疫ワクチン | |
US8163887B2 (en) | Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines | |
JP2008115196A (ja) | 多段階カスケード増強ワクチンの効果を高めるための免疫接合体 | |
US5091178A (en) | Tumor therapy with biologically active anti-tumor antibodies | |
JP4716350B2 (ja) | 潜伏期膜タンパク質に対する抗体およびそれらの使用 | |
US7794710B2 (en) | Methods of enhancing T cell responsiveness | |
JP4854912B2 (ja) | 癌に対する抗体 | |
JP2000511403A (ja) | 抗癌胎児抗原抗イディオタイプ抗体のヒト化と腫瘍ワクチンとしての使用及びターゲッティング用途のための使用 | |
JP2008505645A (ja) | ガン細胞に特異的な抗体を見出すための方法およびそれによって見出される抗体 | |
JPH11509558A (ja) | 免疫反応を惹起するための、多数エピトープ含有抗原の再構成法および組成物 | |
MXPA01007148A (es) | Uso de anticuerpos para vacunacion anti-cancer. | |
JPS62205034A (ja) | 生物活性抗腫瘍抗体による腫瘍療法 | |
US6440733B1 (en) | Monoclonal antibodies recognizing antigens on the surface of endothelial cells of tumor vessel | |
Kirby et al. | Immunotherapy of ovarian cancer | |
Eccles | c-erbB-2 as a target for immunotherapy | |
Muvaffak et al. | The use of antibodies in diagnosis and therapy of cancer | |
US20100119514A1 (en) | Antibodies Against Cancer | |
Murray et al. | Therapeutic anticancer antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20031128 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20031128 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20050525 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070116 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070330 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070521 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070717 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071002 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080207 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080306 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080310 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080227 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080310 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080424 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20080508 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20081104 |